InSilicoTrials

𝗪𝗵𝗮𝘁 𝗮 𝘄𝗲𝗲𝗸 𝗮𝘁 𝗕𝗜𝗢 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝟮𝟬𝟮𝟲! Last week, BIO International Convention in San Diego brought together the global biotech community for an inspiring week of innovation, collaboration, and new opportunities. InSilicoTrials was proud to be part of the world's leading biotechnology event, represented by our CEO Mario Torchia and CBO Sofia Stathopoulos. Throughout the event, we had the opportunity to connect with industry leaders, engage in strategic discussions, and showcase how our simulation-based solutions are helping pharmaceutical companies reduce time, costs, and risk across the drug development journey. These conversations reinforced the growing role of in silico technologies in making healthcare innovation faster, safer, and more efficient. A special thank you to ITA - Italian Trade Agency for hosting us at the Italian Pavilion. We also had the privilege of working alongside Yann GODFRIN, Ph.D., CEO of Axoltis Pharma, and Larry Zana, CEO of Consegna Pharma Inc., supporting the development of their promising programs through our in silico technologies. Together with Mario Torchia, they presented our collaboration and highlighted how in silico solutions are transforming the way new therapies are developed. Finally, thank you to everyone who visited our booth, shared ideas, and explored future collaboration opportunities with us. We look forward to continuing these conversations. See you next year in Philadelphia, June 7-10! #BIOUSA2026 #InSilicoTrials #BiotechInnovation #DigitalHealth #DrugDevelopment #BIOInternational #BIO2027

𝗛𝗼𝘄 𝗱𝗼 𝘆𝗼𝘂 𝗿𝘂𝗻 𝗮 𝗿𝗶𝗴𝗼𝗿𝗼𝘂𝘀 𝗔𝗟𝗦 𝘁𝗿𝗶𝗮𝗹 𝘄𝗵𝗶𝗹𝗲 𝗲𝗮𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗯𝘂𝗿𝗱𝗲𝗻 𝗼𝗳 𝗽𝗹𝗮𝗰𝗲𝗯𝗼 𝗼𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀?   At ENCALS 2026 in Madrid, our Head of AI & Statistics, Paolo Messina, presents a methodological framework that puts synthetic patient profiles to work on exactly that question.   Externally validated models trained on large ALS datasets, predict each patient's expected untreated disease course, then use those predictions to adjust the analysis for prognosis, giving more precision from the same patients, and to build digital-twin controls that enrich the placebo arm. "𝗔𝘂𝗴𝗺𝗲𝗻𝘁𝗲𝗱 𝗣𝗹𝗮𝗰𝗲𝗯𝗼 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 𝗨𝘀𝗶𝗻𝗴 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗣𝗿𝗼𝗳𝗶𝗹𝗲𝘀 𝗶𝗻 𝗔𝗟𝗦 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗔 𝗠𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸" (#PO127)   📍 June 24 📍 Exhibition Area 🕔 17:20 – 19:00 Stop by our poster to discuss how synthetic patient profiles and digital twins can advance ALS drug development and clinical research. #ENCALS2026 #ALS #ALSResearch #ClinicalTrials #DigitalTwins #SyntheticData #Biostatistics #DrugDevelopment

𝗠𝗲𝗲𝘁 𝘂𝘀 𝗮𝘁 𝗣𝗦𝗜 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗕𝗲𝗹𝗳𝗮𝘀𝘁, 𝟭𝟱-𝟭𝟳 𝗝𝘂𝗻𝗲!   Sofia Azevedo, Principal Biostatistician Analyst, will be representing InSilicoTrials at the PSI 2026 Annual Conference, one of the leading events for statisticians, data scientists, and clinical development professionals in the pharmaceutical industry.   Sofia will present a poster titled: “𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝘀 𝗮 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗥𝗼𝗯𝘂𝘀𝘁𝗻𝗲𝘀𝘀 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁, 𝗦𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀, 𝗮𝗻𝗱 𝗘𝘅𝗽𝗹𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗦𝘂𝗽𝗽𝗼𝗿𝘁”   🔹𝗣𝗼𝘀𝘁𝗲𝗿: #𝗣𝟬𝟴𝟬 🔹𝗣𝗼𝘀𝘁𝗲𝗿 𝗥𝗲𝘃𝗶𝗲𝘄: 𝗘𝘅𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻 𝗛𝗮𝗹𝗹 | 𝗠𝗼𝗻𝗱𝗮𝘆, 𝗝𝘂𝗻𝗲 𝟭𝟱 | 𝟭𝟳:𝟰𝟱-𝟭𝟴:𝟰𝟱   We have also been selected for the “𝗚𝗼𝗻𝗲 𝗶𝗻 𝟰𝟱 𝗦𝗲𝗰𝗼𝗻𝗱𝘀” 𝗦𝗲𝘀𝘀𝗶𝗼𝗻, where Sofia will present a rapid-fire overview of our work immediately before the poster session: 🔹𝗛𝗮𝗹𝗹 𝟭𝗮, 𝗠𝗼𝗻𝗱𝗮𝘆, 𝗝𝘂𝗻𝗲 𝟭𝟱 | 𝟭𝟳:𝟬𝟬-𝟭𝟳:𝟰𝟱   If you're attending PSI 2026, stop by to meet Sofia and discover how InSilicoTrials is leveraging AI-powered simulation and virtual patient technologies to enhance clinical development, strengthen evidence generation, and support data-driven decisions.   🔗 Learn more about the conference: https://lnkd.in/gQwds52b PSI: Statisticians in the Pharmaceutical Industry #PSI2026 #Biostatistics #ClinicalTrials #SyntheticData #VirtualPatients #DecisionMaking #InSilicoTrials

This month, our CEO Mario Torchia and CBO Sofia Stathopoulos will be attending BIO International Convention 2026 in San Diego, June 22-25, one of the biggest international events in healthcare and life sciences.   BIO is much more than a single conference. It's a full week of events, receptions and partnering sessions where the real conversations happen, and we're looking forward to being part of it.   Come find us at the ITA Pavilion, 𝗕𝗼𝗼𝘁𝗵 #𝟰𝟭𝟯𝟰, and hear directly from our team how in silico technologies are helping reshape drug development, cutting time, reducing costs and bringing down the reliance on traditional trial methods.   Connect with us through the BIO One-on-One Partnering platform or directly here on LinkedIn.   Whether you're exploring new approaches to your pipeline or just curious about what we're building, we'd love to have a conversation.   Looking forward to seeing you in San Diego! #BIOUSA2026 #InSilicoTrials #DrugDevelopment #Networking #Partnering #SanDiego

InSilicoTrials is excited to announce a collaboration with Microsoft to integrate MOL2CLIN into Microsoft Discovery. Cancer drug development begins with thousands of molecules. Only a few ever reach patients. Too often, important questions are answered late, after time, resources and patient risk have already been committed. 𝗠𝗢𝗟𝟮𝗖𝗟𝗜𝗡 𝘄𝗮𝘀 𝗯𝘂𝗶𝗹𝘁 𝘁𝗼 𝗵𝗲𝗹𝗽 𝗰𝗵𝗮𝗻𝗴𝗲 𝘁𝗵𝗮𝘁. Integrated into Microsoft Discovery, an enterprise agentic R&D platform, MOL2CLIN brings mechanistic, patient-level simulation into AI-driven discovery workflows. This helps oncology teams evaluate pharmacokinetics, target engagement, tumor response, safety signals, and virtual clinical outcomes earlier in development. For patients, earlier evidence matters. It can help teams make more informed decisions, design better studies, reduce unnecessary risk, and move the most promising therapies forward with greater confidence. Oncology is an important starting point, and this approach will support better decisions across additional therapeutic areas. The future of drug development should be more predictive, more efficient, and more centered on patients. 𝗧𝗵𝗮𝘁 𝗶𝘀 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝘄𝗲 𝗮𝗿𝗲 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘁𝗼𝘄𝗮𝗿𝗱. Read the full blog here: https://lnkd.in/eugqrZVA   #Oncology #MicrosoftDiscovery #InSilicoTrials #MOL2CLIN #DrugDiscovery #AIinPharma #DigitalTwins #VirtualClinicalTrials #DrugDevelopment

𝗪𝗲'𝗿𝗲 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝗮 𝗻𝗲𝘄 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗲𝗿𝘀𝗲 𝗣𝗿𝗼𝗷𝗲𝗰𝘁, 𝘄𝗵𝗲𝗿𝗲 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗶𝘀 𝗮 𝗸𝗲𝘆 𝗽𝗮𝗿𝘁𝗻𝗲𝗿.   Cardiac toxicity is one of the leading reasons drugs fail in development, often too late, and at enormous cost. What if we could predict that risk much earlier, using in vitro data alone?   Our new paper in the International Journal of Molecular Sciences MDPI presents a framework that combines target affinity, drug exposure, and plasma protein binding to flag cardiovascular risk before animal studies even begin. Applied to a curated dataset of 𝟭,𝟯𝟭𝟴 𝗱𝗿𝘂𝗴𝘀, we identified 18 pharmacological target classes associated with elevated cardiac risk. The signal is striking: 80% of the highest-concern drugs linked to these targets, versus only 12% of drugs with no concern.   Thank you to our partners at The Jackson Laboratory for their essential contribution to this work.   Read the full paper to learn more: https://lnkd.in/dKVu59CR   Simona Catozzi Fianne Sips Niccolò Totis, MD, PhD Marc-Antonio Bisotti Sofia Stathopoulos Mario Torchia Luca Emili Vincenzo Carbone, PhD Candice Baker Matt Mahoney Daniel Röshammar #DrugSafety #Cardiotoxicity #CARDIOVERSE #InSilicoTrials #JacksonLaboratory

𝗕𝗲𝗳𝗼𝗿𝗲 𝘁𝗵𝗲 𝗙𝗶𝗿𝘀𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁: 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗜𝗻 𝗦𝗶𝗹𝗶𝗰𝗼: 𝗙𝗿𝗼𝗺 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲 𝘁𝗼 𝗖𝗹𝗶𝗻𝗶𝗰   9 out of 10 oncology drug candidates fail in clinical trials. The cost, in time, money, and missed opportunities for patients, is enormous. What if we could predict failure before enrolling a single patient?   That's exactly what 𝗠𝗢𝗟𝟮𝗖𝗟𝗜𝗡 is built for, and the focus of our brand new white paper. Our fully integrated in silico workflow takes a compound from molecular structure all the way to a predicted clinical trial outcome, chaining pharmacokinetics, target engagement, tumor response, and safety into a rigorous, mechanistic, human-guided pipeline.   Discover more about this crucial topic in our new white paper "𝗕𝗲𝗳𝗼𝗿𝗲 𝘁𝗵𝗲 𝗙𝗶𝗿𝘀𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁: 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗜𝗻 𝗦𝗶𝗹𝗶𝗰𝗼: 𝗙𝗿𝗼𝗺 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲 𝘁𝗼 𝗖𝗹𝗶𝗻𝗶𝗰". And come meet us at 𝗔𝗦𝗖𝗢 𝟮𝟬𝟮𝟲 (29 May - June 2, Chicago), the most influential conference in oncology, where, our CEO Mario Torchia and CBO Sofia Stathopoulos, will be attending and talking about how in silico simulation can fundamentally change the way oncology drug candidates are selected: earlier, faster, and with greater confidence.   Read the full white paper here: https://lnkd.in/eFXqpy7w American Society of Clinical Oncology (ASCO) #DrugDevelopment #Oncology #Molecule #Clinic #InSilicoTrials #ASCO2026

𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝘁𝗵𝗲 𝗔𝗦𝗖𝗢 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 𝗻𝗲𝘅𝘁 𝘄𝗲𝗲𝗸!   The American Society of Clinical Oncology (ASCO) Annual Meeting brings together the global oncology community to shape the future of cancer care, and we’re excited to be part of it once again.   Our CEO, Mario Torchia, and Chief Business Officer, Sofia Stathopoulos, will be in Chicago to meet with innovators, researchers, and leaders who are driving a real impact in oncology.   At InSilicoTrials, we help pharma and biotech teams accelerate oncology research through advanced in silico technologies and regulatory-compliant solutions, supporting smarter decision-making, reducing development risk, and helping bring better therapies to patients faster.   Meet us at ASCO! If you're attending and would like to explore how AI and simulation can support your oncology pipeline, feel free to connect with us through the BIO Partnering for Oncology platform.   See you in Chicago! Biotechnology Innovation Organization American Society of Clinical Oncology (ASCO) #ASCO2026 #Oncology #InSilicoTrials #DrugDevelopment 

May is ALS Awareness Month. 💙   ALS is a devastating disease, progressive, relentless, and still without a cure. Clinical trials are one of our best tools to change that. But running them in ALS is hard: patients are few, the disease progresses fast, and asking someone to receive a placebo for months carries a real human cost.   At InSilicoTrials, we believe technology can help.   This June, we'll be presenting our work at 𝗘𝗡𝗖𝗔𝗟𝗦 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗠𝗮𝗱𝗿𝗶𝗱, the leading European conference dedicated to curing ALS. Our poster "𝗔𝘂𝗴𝗺𝗲𝗻𝘁𝗲𝗱 𝗣𝗹𝗮𝗰𝗲𝗯𝗼 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 𝗨𝘀𝗶𝗻𝗴 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗣𝗿𝗼𝗳𝗶𝗹𝗲𝘀 𝗶𝗻 𝗔𝗟𝗦 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗔 𝗠𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸" showcases how 𝘪𝘯 𝘴𝘪𝘭𝘪𝘤𝘰 models can create virtual placebo patients, reducing the number of real patients exposed to placebo in clinical trials, without compromising scientific rigor. We applied this approach to the 𝗦𝗘𝗔𝗟𝗦 𝘀𝘁𝘂𝗱𝘆, a real clinical trial evaluating a new treatment for ALS.   Our head of AI & Statistics, Paolo Messina, will be presenting our work in Madrid: 𝗝𝘂𝗻𝗲 𝟮𝟰 | 𝟭𝟳:𝟮𝟬–𝟭𝟵:𝟬𝟬 📍 𝗘𝘅𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻 𝗔𝗿𝗲𝗮 We hope to see you there.   Less placebo. Better science. More hope for patients.   #ALSAwarenessMonth #ALS #InSilicoTrials #ClinicalTrials #DrugDevelopment #ENCALS

The 2026 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗿𝘀 𝗶𝗻 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗦𝘂𝗺𝗺𝗶𝘁, organized by Advanced Research Projects Agency for Health (ARPA-H), took place last week, bringing together academia, industry, and government to showcase cutting-edge, data-driven innovations in biomedical research.   InSilicoTrials was proud to be represented by our Head of R&I, Vincenzo Carbone, PhD, alongside Matt Mahoney, Principal Computational Scientist at The Jackson Laboratory, and Brian Carlson, Research Associate Professor at the University of Michigan. Our work was presented as part of the “𝗖𝗔𝗥𝗗𝗜𝗢𝗩𝗘𝗥𝗦𝗘 – 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗼𝗳 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗥𝗶𝘀𝗸 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗗𝗮𝘁𝗮-𝗱𝗿𝗶𝘃𝗲𝗻 𝗜𝗻 𝗦𝗶𝗹𝗶𝗰𝗼 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗳𝗼𝗿 𝗦𝗮𝗳𝗲𝘁𝘆 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻” project, within the ARPA-H CATALYST program, where InSilicoTrials and The Jackson Laboratory contributes alongside a consortium of leading partners (JAX-NYSCF Collaborative, UConn Health, and the University of Michigan). CARDIOVERSE aims to transform cardiac safety assessment in drug development through: • AI-driven prediction of cardiotoxicity • Integration of multi-scale, mechanistic heart models • Data-driven, human-relevant approaches to preclinical testing   It was a great opportunity to connect with the rest of CATALYST Performing Teams and the ARPA-H community, focused on accelerating biomedical discovery through digital innovation. And a huge thank you to Andy Kilianski and his team for organizing such an impactful event!   #InSilicoTrials #CARDIOVERSE #ARPAH #InSilico #AI #CardiacSafety